




Gastrointestinal Cancer—Colorectal and Anal
Oncoletter provides you with quotes from the abstract's conclusions. To see more, go the ASCO Meeting Library while clicking on the link of the study-titles (to see videos and slides needs a payable registration)
Salvatore Siena, Maria Di Bartolomeo, Kanwal Pratap Singh Raghav, et al.
--------------------------------------------------------------------------------------------------------------------------------------------------------
--------------------------------------------------------------------------------------------------------------------------------------------------------
--------------------------------------------------------------------------------------------------------------------------------------------------------
--------------------------------------------------------------------------------------------------------------------------------------------------------
Read the comment in the ASCO DAILY NEWS:
--------------------------------------------------------------------------------------------------------------------------------------------------------
4005 A randomized phase II/III trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone for liver metastasis from colorectal cancer: JCOG0603 study.
--------------------------------------------------------------------------------------------------------------------------------------------------------
--------------------------------------------------------------------------------------------------------------------------------------------------------
--------------------------------------------------------------------------------------------------------------------------------------------------------
e16053 Meta-analysis and systematic review of the cardiotoxicity of TAS-102
Carlos Alberto Lopez, Elham Azimi-Nekoo, Su Yun Chung, et al.
The abstract concludes:
Unlike other fluoropyrimidines, TAS-102 appears to be a cardiogentle drug, with no increased risk of cardiac events compared to placebo. Since fluoropyrimidines remain the backbone of treatment for gastrointestinal malignancies, TAS-102 can offer an alternative to patients who developed cardiotoxicities from other agents. Prospective studies with consideration of cardiac risk factors are required.
David H. Ilson: ASCO 2020 Report — Gastrointestinal Cancer Key trials in colorectal, esophageal, pancreatic, and hepatocellular cancer
|